Table 3.
Treatment-related adverse events
| TRAEs, n (%) | All patients (n = 62) | |||
|---|---|---|---|---|
| Grade 1–2 | Grade 3 | Grade 4 | Grade 5 | |
| Patients with at least one TRAE | 24 (38.7) | 27 (43.5) | 5 (8.1) | 5 (8.1) |
| TRAEs (all grades) in ≥15% of patients: | ||||
| Anemia | 33 (53.2) | 5 (8.1) | 0 | 0 |
| Nausea | 33 (53.2) | 1 (1.6) | 0 | 0 |
| Vomiting | 32 (51.6) | 0 | 0 | 0 |
| Aspartate aminotransferase increased | 31 (50.0) | 0 | 0 | 0 |
| Decreased appetite | 29 (46.8) | 0 | 0 | 0 |
| Hypoesthesia | 29 (46.8) | 0 | 0 | 0 |
| Platelet count decreased | 24 (38.7) | 1 (1.6) | 0 | 0 |
| Alanine aminotransferase increased | 22 (35.5) | 1 (1.6) | 0 | 0 |
| Epistaxis | 22 (35.5) | 0 | 0 | 0 |
| Diarrhea | 21 (33.9) | 2 (3.2) | 0 | 0 |
| Proteinuria | 21 (33.9) | 0 | 0 | 0 |
| Neutrophil count decreased | 19 (30.6) | 5 (8.1) | 0 | 0 |
| Hypoalbuminemia | 19 (30.6) | 1 (1.6) | 0 | 0 |
| White blood cell count decreased | 19 (30.6) | 0 | 0 | 0 |
| Gingival bleeding | 17 (27.4) | 0 | 0 | 0 |
| Blood bilirubin increased | 15 (24.2) | 1 (1.6) | 0 | 0 |
| Pruritus | 13 (21.0) | 0 | 0 | 0 |
| Malaise | 12 (19.4) | 2 (3.2) | 0 | 0 |
| Occult blood positive | 12 (19.4) | 0 | 0 | 0 |
| Mouth hemorrhage | 12 (19.4) | 0 | 0 | 0 |
| Dizziness | 12 (19.4) | 0 | 0 | 0 |
| Fatigue | 11 (17.7) | 2 (3.2) | 0 | 0 |
| Constipation | 11 (17.7) | 0 | 0 | 0 |
| Hypothyroidism | 11 (17.7) | 0 | 0 | 0 |
| Palmar-plantar erythrodysesthesia syndrome | 10 (16.1) | 2 (3.2) | 0 | 0 |
| Rash | 10 (16.1) | 0 | 0 | 0 |
TRAEs, treatment-related adverse events